CONMED (CNMD) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
18 May, 2026Opening remarks and agenda
Meeting called to order at 11:30 A.M. on May 18, 2026, with all Board members and independent auditors present.
Recognition given to retiring Board member Brian Concannon for his service and leadership.
Rules of conduct and notice of meeting were confirmed as properly distributed to all stockholders.
Board and executive committee updates
Seven Director nominees were introduced for election to serve a one-year term until the 2027 annual meeting.
Brian Concannon retired from the Board in accordance with term limits.
Shareholder proposals
Three proposals presented: election of Directors, advisory approval of executive compensation, and ratification of the independent auditor.
No additional proposals were introduced by stockholders.
Partial view of Summaries dataset, powered by Quartr API
Latest events from CONMED
- 2025 guidance targets 4–6% revenue growth and $4.25–$4.40 adjusted EPS, with supply chain and currency headwinds.CNMD
Q4 20248 Jul 2026 - Q3 sales up 4.0%–4.3%, adjusted EPS up 16.7%, with CEO transition and hurricane impacts.CNMD
Q3 20248 Jul 2026 - Supply chain recovery, strong AirSeal performance, and margin growth drive a positive outlook.CNMD
2024 Wells Fargo Healthcare Conference8 Jul 2026 - Q2 sales and margins improved, but full-year guidance was reduced amid supply chain delays.CNMD
Q2 20248 Jul 2026 - Net income and margins rose despite a 1.3% sales drop; organic growth outlook improved.CNMD
Q1 202630 Apr 2026 - 2026 guidance targets $1.345–$1.450B revenue and $4.25–$4.45 EPS, led by innovation and portfolio focus.CNMD
44th Annual J.P. Morgan Healthcare Conference16 Apr 2026 - Key votes include board elections, executive pay approval, and auditor ratification.CNMD
Proxy filing7 Apr 2026 - Strong 2025 growth, board refreshment, and enhanced governance with key shareholder votes ahead.CNMD
Proxy filing7 Apr 2026 - 2025 sales and adjusted EPS rose, with 2026 guidance projecting further organic growth.CNMD
Q4 20253 Feb 2026